Immunome prices $400M public offering of 18.6M shares at $21.50 per share

Immunome Inc.

Public offering of 18,625,000 shares at $21.50/share; gross proceeds ~$400M.
Underwriters granted 30-day option for up to 2,793,750 additional shares at same price.
Offering expected to close December 18, 2025; joint bookrunners include Leerink, J.P. Morgan, TD Cowen, Goldman Sachs, Guggenheim.
All shares sold by Immunome; proceeds before underwriting discounts and expenses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.